Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection
| dc.date.accessioned | 2018-09-14T11:15:03Z | |
| dc.date.available | 2017-02-28T23:13:49Z | |
| dc.date.available | 2016-07-05 | en_US |
| dc.date.available | 2016-07-05 | en_US |
| dc.date.available | 2016-07-05 | en_US |
| dc.date.available | 2016-07-05 | en_US |
| dc.date.available | 2016-07-05 | en_US |
| dc.date.available | 2016-07-05 | en_US |
| dc.date.available | 2016-07-05 | en_US |
| dc.date.available | 2016-07-05 | en_US |
| dc.date.available | 2016-07-05 | en_US |
| dc.date.available | 2018-09-14T11:15:03Z | |
| dc.date.issued | 2016-08-19 | en_US |
| dc.description.abstract | Zika virus (ZIKV), a mosquito-borne flavivirus with homology to Dengue virus (DENV), has become a public health emergency. By characterizing memory lymphocytes from ZIKV-infected patients, we dissected ZIKV-specific and DENV-cross-reactive immune responses. Antibodies to nonstructural protein 1 (NS1) were largely ZIKV-specific and were used to develop a serological diagnostic tool. In contrast, antibodies against E protein domain I/II (EDI/II) were cross-reactive and, although poorly neutralizing, potently enhanced ZIKV and DENV infection in vitro and lethally enhanced DENV disease in mice. Memory T cells against NS1 or E proteins were poorly cross-reactive, even in donors preexposed to DENV. The most potent neutralizing antibodies were ZIKV-specific and targeted EDIII or quaternary epitopes on infectious virus. An EDIII-specific antibody protected mice from lethal ZIKV infection, illustrating the potential for antibody-based therapy. | |
| dc.identifier.uri | http://localhost:8080/dspace7/handle/123456789/176 | |
| dc.language | English | en_US |
| dc.title | Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection | en_US |
| dc.type | Journal Article |